Bloomberg the Company & Products

Bloomberg Anywhere Login


Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.


Financial Products

Enterprise Products


Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000


Industry Products

Media Services

Follow Us

Last 1,805 GBp
Change Today +25.00 / 1.40%
Volume 74.5K
HCM On Other Exchanges
As of 12:27 PM 04/24/15 All times are local (Market data is delayed by at least 15 minutes).

hutchison china meditech ltd (HCM) Snapshot

1,780 GBp
Previous Close
1,780 GBp
Day High
1,805 GBp
Day Low
1,770 GBp
52 Week High
04/21/15 - 1,850 GBp
52 Week Low
05/16/14 - 750.00 GBp
Market Cap
Average Volume 10 Days
0.09 GBp
Shares Outstanding
Dividend Yield

Related News

No related news articles were found.

hutchison china meditech ltd (HCM) Related Businessweek News

No Related Businessweek News Found

hutchison china meditech ltd (HCM) Details

Hutchison China MediTech Limited engages in the research, development, manufacture, and sale of pharmaceuticals and health oriented consumer products primarily in the People’s Republic of China. It operates through three segments: China Healthcare, Drug Research and Development, and Consumer Products. The company manufactures, distributes, and sells over-the-counter, prescription, and health supplements products under the Bai Yun Shan and Shang Yao brands; and offers drug research and development services. It also offers traditional Chinese medicine products in cardiovascular and cold/flu therapeutic areas. In addition, the company develops clinical drug candidates, including HMPL-004 that is in Phase III clinical trials for ulcerative colitis and Crohn’s disease; Fruquintinib, which is in Phase III clinical trial for the treatment of colorectal, non-small cell lung, and gastric cancer; and Sulfatinib, a Phase 1b clinical trial product for neuroendocrine tumours, as well as Epitinib for treating non-small cell lung cancer. Further, it offers Theliatinib, a Phase I clinical trial product for the treatment of solid tumours; AZD6094 that is in Phase 1b clinical trial for treating non-small cell lung and gastric cancer; HMPL-523 and HMPL-689, which are preclinical stage products for the treatment of hematological cancers; and HMPL-453 that is in preclinical stage for the treatment of solid tumours. The company also offers organic and natural food, beverage, baby, and beauty care products; and distributes organic and natural products. Hutchison China MediTech Limited has strategic collaborations with multinational pharmaceutical and healthcare companies, including AstraZeneca AB (Publ); Eli Lilly and Company; Janssen Pharmaceuticals, Inc.; and Nestlé Health Science SA. The company was founded in 2000 and is based in Hong Kong, Hong Kong. Hutchison China MediTech Limited is a subsidiary of Hutchison Healthcare Holdings Limited.

Founded in 2000

hutchison china meditech ltd (HCM) Top Compensated Officers

Chief Executive Officer, Executive Director, ...
Total Annual Compensation: $920.4K
Chief Financial Officer and Executive Directo...
Total Annual Compensation: $445.7K
Compensation as of Fiscal Year 2013.

hutchison china meditech ltd (HCM) Key Developments

Hutchison China Meditech Reports Consolidated Earnings Results for the Year Ended December 31, 2014

Hutchison China Meditech reported consolidated earnings results for the year ended December 31, 2014. In 2014, the company delivered high revenue growth, with consolidated group revenue up 100% to $91.8 million against $46.0 million a year ago. This growth was driven primarily by the establishment of the new Hutchison Sinopharm business which recorded $50.2 million in sales (2013: nil). The group's full year operating profit was $10.2 million against $9.6 million as a result of improved operating profitability in the China Healthcare (up 21% to $24.8 million) and Consumer Products Divisions (up 209% to $2.8 million), but offset by increased clinical trial expenditures in the Drug R&D Division. Profit before taxation was $6,584,000 against $10,070,000 a year ago. In total, the group's net profit attributable to the company’s equity holders was $5.4 million compared to $5.9 million in 2013 with profit per share of 10.2 cents compared to a profit of 11.4 cents per share in 2013, as the company continues to balance a dramatic increase in clinical trial activity on seven new drug candidates with rapidly increasing profit in the China Healthcare Division. Net cash generated from operating activities was $13,360,000 against $5,028,000 a year ago. Purchase of property, plant and equipment was $3,729,000 against $2,500,000 a year ago.

Hutchison China MediTech Ltd., Annual General Meeting, Apr 24, 2015

Hutchison China MediTech Ltd., Annual General Meeting, Apr 24, 2015., at 10:00 GMT Standard Time. Location: 4th Floor, Hutchison House.

Hutchison China MediTech Ltd. to Report Fiscal Year 2014 Final Results on Feb 26, 2015

Hutchison China MediTech Ltd. announced that they will report fiscal year 2014 final results on Feb 26, 2015


Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
HCM:LN 1,805.00 GBp +25.00

HCM Competitors

Market data is delayed at least 15 minutes.

Company Last Change
No competitor information is available for HCM.
View Industry Companies

Industry Analysis


Industry Average

Valuation HCM Industry Range
Price/Earnings 100.0x
Price/Sales 15.8x
Price/Book 15.3x
Price/Cash Flow 270.8x
TEV/Sales 15.8x

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact HUTCHISON CHINA MEDITECH LTD, please visit Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at